Find Funding Opportunities

The purpose of this notice is to inform applicant of a change to the Application and Submission Information - Post Submission Materials for RFA-NS-23-026 "BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)".

The National Institute of Neurological Disorders and Stroke (NINDS) has launched a newChallenge Competition, the NINDS Rigor Champions Prize. This Notice is being provided to allow potential entrants sufficient time to participate in the Challenge and assemble their teams (if applicable) and submit entries to the Challenge. The Challenge is currentlyopen for submissions through August 15th, 2023. NINDS intends to award up to five monetary prizes of $10,000 each. Additional information about the planned Challenge competition is provided below.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities.The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/) (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in increasing the institution's contribution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated

This Notice is a Request for Information (RFI) inviting comments and suggestions on National Institutes of Healths (NIH) key strategic approaches to develop a Herpes Simplex Virus Strategic Plan.

Effective immediately, the Funding Opportunity AnnouncementRFA-TR-22-013 "Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed) is terminated. Applications submitted toRFA-TR-22-013 will not be reviewed. NIH has reissued this Funding Opportunity Announcement asRFA-TR-23-011 "Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)."

This NOT is to require applicants to contact NINDS staff and get prior approval for $500K applications.

Effective immediately, the Funding Opportunity AnnouncementPAR-22-058 Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)is terminated. Applications submitted toPAR-22-058 will not be reviewed. NIH has reissued this Funding Opportunity Announcement asTEMP-21186 Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed).

Effective immediately, the Funding Opportunity AnnouncementRFA-TR-22-011 "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) is terminated. Applications submitted toRFA-TR-22-011 will not be reviewed. NIH has reissued this Funding Opportunity Announcement as RFA-TR-23-010 "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)

The purpose of this notice is to inform applicants of a correction to Section IV. Application and Submission Information for RFA-NS-24-022 "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional)".

Change to number of applications per inst allowed.